Base de dados : MEDLINE
Pesquisa : D02.065.589.099.750.875 [Categoria DeCS]
Referências encontradas : 993 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 100 ir para página                         

  1 / 993 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28257816
[Au] Autor:Araoka H; Baba M; Okada C; Abe M; Kimura M; Yoneyama A
[Ad] Endereço:Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan. Electronic address: h-araoka@toranomon.gr.jp.
[Ti] Título:Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.
[So] Source:Int J Infect Dis;58:18-21, 2017 May.
[Is] ISSN:1878-3511
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. METHODS: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed. RESULTS: SXT+LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT+TIM showed synergy in 71, and no interactions in 18. SXT+MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT+fluoroquinolone was not associated with improved prognosis compared with monotherapy. CONCLUSIONS: The in vitro data indicated that SXT+TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT+fluoroquinolone combination therapy for S. maltophilia infection.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Neoplasias/complicações
Stenotrophomonas maltophilia
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Bacteriemia/tratamento farmacológico
Ácidos Clavulânicos
Quimioterapia Combinada
Feminino
Fluoroquinolonas/uso terapêutico
Infecções por Bactérias Gram-Negativas/complicações
Infecções por Bactérias Gram-Negativas/microbiologia
Seres Humanos
Levofloxacino/uso terapêutico
Masculino
Meia-Idade
Minociclina/uso terapêutico
Neoplasias/tratamento farmacológico
Stenotrophomonas maltophilia/isolamento & purificação
Ticarcilina
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Clavulanic Acids); 0 (Fluoroquinolones); 6GNT3Y5LMF (Levofloxacin); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 86482-18-0 (ticarcillin-clavulanic acid); F93UJX4SWT (Ticarcillin); FYY3R43WGO (Minocycline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170305
[St] Status:MEDLINE


  2 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28095794
[Au] Autor:Robert J; Pantel A; Merens A; Meiller E; Lavigne JP; Nicolas-Chanoine MH; ONERBA's carbapenem resistance study group
[Ad] Endereço:Sorbonne Universités, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Eq 13, F-75013, Paris, France. jerome.robert0@upmc.fr.
[Ti] Título:Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
[So] Source:BMC Infect Dis;17(1):78, 2017 Jan 17.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Carbapenemase-producing Enterobacteriaceae (CPE) are difficult to identify among carbapenem non-susceptible Enterobacteriaceae (NSE). We designed phenotypic strategies giving priority to high sensitivity for screening putative CPE before further testing. METHODS: Presence of carbapenemase-encoding genes in ertapenem NSE (MIC > 0.5 mg/l) consecutively isolated in 80 French laboratories between November 2011 and April 2012 was determined by the Check-MDR-CT103 array method. Using the Mueller-Hinton (MH) disk diffusion method, clinical diameter breakpoints of carbapenems other than ertapenem, piperazicillin+tazobactam, ticarcillin+clavulanate and cefepime as well as diameter cut-offs for these antibiotics and temocillin were evaluated alone or combined to determine their performances (sensitivity, specificity, positive and negative likelihood ratios) for identifying putative CPE among these ertapenem-NSE isolates. To increase the screening specificity, these antibiotics were also tested on cloxacillin-containing MH when carbapenem NSE isolates belonged to species producing chromosomal cephalosporinase (AmpC) but Escherichia coli. RESULTS: Out of the 349 ertapenem NSE, 52 (14.9%) were CPE, including 39 producing OXA-48 group carbapenemase, eight KPC and five MBL. A screening strategy based on the following diameter cut offs, ticarcillin+clavulanate <15 mm, temocillin <15 mm, meropenem or imipenem <22 mm, and cefepime <26 mm, showed 100% sensitivity and 68.1% specificity with the better likelihood ratios combination. The specificity increased when a diameter cut-off <32 mm for imipenem (76.1%) or meropenem (78.8%) further tested on cloxacillin-containing MH was added to the previous strategy for AmpC-producing isolates. CONCLUSION: The proposed strategies that allowed for increasing the likelihood of CPE among ertapenem-NSE isolates should be considered as a surrogate for carbapenemase production before further CPE confirmatory testing.
[Mh] Termos MeSH primário: Algoritmos
Proteínas de Bactérias/análise
Carbapenêmicos/metabolismo
Farmacorresistência Bacteriana
Enterobacteriaceae/metabolismo
beta-Lactamases/análise
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Proteínas de Bactérias/metabolismo
Carbapenêmicos/farmacologia
Cefalosporinas/farmacologia
Ácidos Clavulânicos/farmacologia
Enterobacteriaceae/efeitos dos fármacos
Enterobacteriaceae/genética
Enterobacteriaceae/fisiologia
Seres Humanos
Imipenem/metabolismo
Imipenem/farmacologia
Testes de Sensibilidade Microbiana
Ácido Penicilânico/análogos & derivados
Ácido Penicilânico/farmacologia
Penicilinas/farmacologia
Tienamicinas/metabolismo
Tienamicinas/farmacologia
Ticarcilina/farmacologia
beta-Lactamases/metabolismo
beta-Lactamas/metabolismo
beta-Lactamas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Carbapenems); 0 (Cephalosporins); 0 (Clavulanic Acids); 0 (Penicillins); 0 (Thienamycins); 0 (beta-Lactams); 03QB156W6I (temocillin); 71OTZ9ZE0A (Imipenem); 807PW4VQE3 (cefepime); 86482-18-0 (ticarcillin-clavulanic acid); 87-53-6 (Penicillanic Acid); EC 3.5.2.6 (beta-Lactamases); EC 3.5.2.6 (carbapenemase); F93UJX4SWT (Ticarcillin); FV9J3JU8B1 (meropenem); G32F6EID2H (ertapenem); SE10G96M8W (tazobactam)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-016-2174-y


  3 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27294684
[Au] Autor:Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y
[Ad] Endereço:1 Department of Internal Medicine, CHA Bundang Medical Center, CHA University , Seongnam, Korea.
[Ti] Título:Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
[So] Source:Microb Drug Resist;23(2):163-168, 2017 Mar.
[Is] ISSN:1931-8448
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Trimethoprim-sulfamethoxazole is the first-line antimicrobial combination for Stenotrophomonas maltophilia infections. However, allergy or intolerance and increasing resistance limit the use of trimethoprim-sulfamethoxazole. Quinolones can be used as an alternative therapeutic option, but resistance can emerge rapidly during therapy. We analyzed the contribution of SmeABC and SmeDEF efflux pumps to levofloxacin resistance in clinical isolates of S. maltophilia. Nonduplicate clinical isolates of S. maltophilia were collected in 2010 from 11 university hospitals (n = 102). Fifty-five levofloxacin nonsusceptible (minimum inhibitory concentration [MIC] ≥4 µg/ml) and 47 susceptible (MIC ≤2 µg/ml) isolates were tested for efflux pump overexpression. Real-time reverse transcription-PCR was performed for amplification and quantification of smeB, smeC, smeD, and smeF mRNA. To determine which antimicrobials were affected by smeD overexpression, the growth rates of a levofloxacin-susceptible S. maltophilia isolate were compared by measuring absorbance of antimicrobial-supplemented Luria-Bertani broth (LB) cultures with or without triclosan. Significant relationships between sme gene overexpression and resistance were observed for smeD against levofloxacin, smeC and smeF against ceftazidime, and smeC against ticarcillin-clavulanate. The mean MICs of moxifloxacin and tigecycline did not significantly differ for isolates with or without overexpression of smeB, smeC, and smeF, but were significantly higher for isolates with smeD overexpression. The mean MICs of amikacin were significantly higher for smeC or smeF overexpressing isolates. Increased growth of a levofloxacin-susceptible isolate was observed in LB with 1/2 MIC levofloxacin in the presence of triclosan. These data suggest that the expression of smeD plays a role in levofloxacin resistance in S. maltophilia.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Proteínas de Bactérias/metabolismo
Levofloxacino/farmacologia
Proteínas de Membrana Transportadoras/metabolismo
Stenotrophomonas maltophilia/efeitos dos fármacos
Stenotrophomonas maltophilia/metabolismo
[Mh] Termos MeSH secundário: Ceftazidima/farmacologia
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Fluoroquinolonas/farmacologia
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Seres Humanos
Testes de Sensibilidade Microbiana/métodos
Minociclina/análogos & derivados
Minociclina/farmacologia
Ticarcilina/farmacologia
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Fluoroquinolones); 0 (Membrane Transport Proteins); 0 (SmeD protein, Stenotrophomonas maltophilia); 6GNT3Y5LMF (Levofloxacin); 70JE2N95KR (tigecycline); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 9M416Z9QNR (Ceftazidime); F93UJX4SWT (Ticarcillin); FYY3R43WGO (Minocycline); U188XYD42P (moxifloxacin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160614
[St] Status:MEDLINE
[do] DOI:10.1089/mdr.2015.0228


  4 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27496417
[Au] Autor:Usarek P; Dobrzaniecka K; Szymanek-Majchrzak K; Sawicka-Grzelak A; Mlynarczyk A; Durlik M; Ciszek M; Paczek L; Chmura A; Kwiatkowski A; Mlynarczyk G
[Ad] Endereço:Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland.
[Ti] Título:Drug Susceptibility Assessment in Stenotrophomonas Maltophilia Strains Isolated From the Blood of Organ Transplantation Recipients in a Warsaw Teaching Hospital During 2011 to 2014.
[So] Source:Transplant Proc;48(5):1411-3, 2016 Jun.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Blood infections with multidrug-resistant Gram-negative carbapenem-resistant bacilli are particularly dangerous and challenging to treat in organ transplant recipients. Resistance to carbapenems may be acquired, for example, in Enterobacteriaceae, Pseudomonas, or Acinetobacter spp. or innate, for example, in Stenotrophomonas maltophilia. The purpose of this study was to analyze blood infections caused by S maltophilia in organ transplant recipients and to compare drug susceptibility of these bacteria and the same species isolated from the blood of other inpatients. METHODS: A total of 26 S maltophilia strains isolated from blood samples of 26 patients (including 14 liver or kidney transplant recipients) hospitalized during 2011 to 2014 were evaluated in this study. Antibiotic susceptibility was determined via E-test and disk diffusion methods. RESULTS: Stenotrophomonas maltophilia strains isolated from blood exhibited sensitivity to trimethoprim/sulfamethoxazole (100%), levofloxacin (96.2%), ciprofloxacin (92.3%), ticarcillin/clavulanic acid (80.8%), and ceftazidime (53.9%). CONCLUSIONS: Because appropriate antibiotic therapy in the case of S maltophilia differs from the standard empirical therapy administered in the case of most other Gram-negative bacilli, early identification of this pathogen is of particular significance. The use of antibiotics to which this pathogen is sensitive eliminates the infection and helps avoid graft loss.
[Mh] Termos MeSH primário: Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Infecções por Bactérias Gram-Negativas/microbiologia
Testes de Sensibilidade Microbiana
Transplante de Órgãos/efeitos adversos
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Ceftazidima/uso terapêutico
Ciprofloxacino/uso terapêutico
Ácidos Clavulânicos/uso terapêutico
Farmacorresistência Bacteriana
Hospitais de Ensino
Seres Humanos
Levofloxacino/uso terapêutico
Stenotrophomonas maltophilia
Ticarcilina/uso terapêutico
Transplantados/estatística & dados numéricos
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Clavulanic Acids); 5E8K9I0O4U (Ciprofloxacin); 6GNT3Y5LMF (Levofloxacin); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 86482-18-0 (ticarcillin-clavulanic acid); 9M416Z9QNR (Ceftazidime); F93UJX4SWT (Ticarcillin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160807
[St] Status:MEDLINE


  5 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27197940
[Au] Autor:Pitondo-Silva A; Gonçalves GB; Stehling EG
[Ad] Endereço:Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Universidade de São Paulo (USP), Ribeirão Preto, Brazil.
[Ti] Título:Heavy metal resistance and virulence profile in Pseudomonas aeruginosa isolated from Brazilian soils.
[So] Source:APMIS;124(8):681-8, 2016 Aug.
[Is] ISSN:1600-0463
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:Pseudomonas aeruginosa is an opportunistic pathogen, which can have several virulence factors that confer on it the ability to cause severe, acute and chronic infections. Thus, the simultaneous occurrence of resistance to antibiotics and heavy metals associated with the presence of virulence genes is a potential threat to human health and environmental balance. This study aimed to investigate the resistance profile to heavy metals and the correlation of this phenotype of resistance to antimicrobials and to investigate the pathogenic potential of 46 P. aeruginosa isolates obtained from the soil of five Brazilian regions. The bacteria were evaluating for antimicrobial and heavy metal resistance, as well as the presence of plasmids and virulence genes. The isolates showed resistance to four different antibiotics and the majority (n = 44) had resistance to aztreonam or ticarcillin, furthermore, 32 isolates showed concomitant resistance to both of these antibiotics. A high prevalence of virulence genes was found, which highlights the pathogenic potential of the studied environmental isolates. Moreover, a high frequency of heavy metal resistance genes was also detected, however, the phenotypic results indicated that other genes and/or mechanisms should be related to heavy metal resistance.
[Mh] Termos MeSH primário: Farmacorresistência Bacteriana
Metais Pesados/toxicidade
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/patogenicidade
Microbiologia do Solo
Fatores de Virulência/genética
[Mh] Termos MeSH secundário: Antibacterianos/metabolismo
Aztreonam/metabolismo
Brasil
Seres Humanos
Testes de Sensibilidade Microbiana
Plasmídeos/análise
Reação em Cadeia da Polimerase
Pseudomonas aeruginosa/genética
Ticarcilina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Metals, Heavy); 0 (Virulence Factors); F93UJX4SWT (Ticarcillin); G2B4VE5GH8 (Aztreonam)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170123
[Lr] Data última revisão:
170123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160521
[St] Status:MEDLINE
[do] DOI:10.1111/apm.12553


  6 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26854365
[Au] Autor:Streeter K; Neuman C; Thompson J; Hatje E; Katouli M
[Ad] Endereço:Genecology Research Centre, School of Health and Sport Sciences, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore DC, 4558, Queensland, Australia.
[Ti] Título:The characteristics of genetically related Pseudomonas aeruginosa from diverse sources and their interaction with human cell lines.
[So] Source:Can J Microbiol;62(3):233-40, 2016 Mar.
[Is] ISSN:1480-3275
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:We investigated a collection of Pseudomonas aeruginosa strains from hospitalised patients (n = 20) and various environmental sources (n = 214) for their genetic relatedness; virulence properties; antibiotic resistance; and interaction with intestinal (Caco-2), renal (A-498), and lung (Calu-3) cell lines. Using RAPD-PCR, we found high diversity among the strains irrespective of their sources, with only 6 common (C) types containing strains from both a clinical and environmental source. Environmental strains belonging to these C-types showed greater adhesion to A-498 cells than did clinical strains (17 ± 13 bacteria/cell versus 13 ± 11 bacteria/cell; p < 0.001), whereas clinical strains showed significantly greater adhesion to Calu-3 and Caco-2 cells than did environmental strains (p < 0.001 for both). The virulence genes and antibiotic resistance profiles of the strains were similar; however, the prevalence of environmental strains carrying both exoS and exoU was significantly (p < 0.0368) higher than clinical strains. While all strains were resistant to ticarcillin and ticarcillin-clavulanic acid, resistance against aztreonam, gentamicin, amikacin, piperacillin, and ceftazidime varied among environmental and clinical strains. These results suggest that environmental strains of P. aeruginosa carry virulence properties similar to clinical strains, including adhesion to various human cell lines, with some strains showing a higher adhesion to specific cell lines, indicating they may have a better ability to cause infection in those sites under predisposing conditions of the host.
[Mh] Termos MeSH primário: Pseudomonas aeruginosa/genética
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Células CACO-2
Ácidos Clavulânicos/farmacologia
Resistência Microbiana a Medicamentos/efeitos dos fármacos
Microbiologia Ambiental
Seres Humanos
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/patogenicidade
Técnica de Amplificação ao Acaso de DNA Polimórfico
Ticarcilina/farmacologia
Virulência/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Clavulanic Acids); 86482-18-0 (ticarcillin-clavulanic acid); F93UJX4SWT (Ticarcillin)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160209
[St] Status:MEDLINE
[do] DOI:10.1139/cjm-2015-0536


  7 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26787686
[Au] Autor:Devos S; Stremersch S; Raemdonck K; Braeckmans K; Devreese B
[Ad] Endereço:Laboratory for Protein Biochemistry and Biomolecular Engineering (L-PROBE), Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
[Ti] Título:Intra- and Interspecies Effects of Outer Membrane Vesicles from Stenotrophomonas maltophilia on ß-Lactam Resistance.
[So] Source:Antimicrob Agents Chemother;60(4):2516-8, 2016 Apr.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The treatment ofStenotrophomonas maltophiliainfection with ß-lactam antibiotics leads to increased release of outer membrane vesicles (OMVs), which are packed with two chromosomally encoded ß-lactamases. Here, we show that these ß-lactamase-packed OMVs are capable of establishing extracellular ß-lactam degradation. We also show that they dramatically increase the apparent MICs of imipenem and ticarcillin for the cohabituating speciesPseudomonas aeruginosaandBurkholderia cenocepacia.
[Mh] Termos MeSH primário: Burkholderia cenocepacia/genética
Vesículas Extracelulares/enzimologia
Pseudomonas aeruginosa/genética
Stenotrophomonas maltophilia/genética
Resistência beta-Lactâmica/genética
beta-Lactamases/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Burkholderia cenocepacia/efeitos dos fármacos
Burkholderia cenocepacia/enzimologia
Membrana Celular/química
Conjugação Genética
Vesículas Extracelulares/química
Expressão Gênica
Transferência Genética Horizontal
Hidrólise
Imipenem/farmacologia
Testes de Sensibilidade Microbiana
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/enzimologia
Stenotrophomonas maltophilia/efeitos dos fármacos
Stenotrophomonas maltophilia/enzimologia
Ticarcilina/farmacologia
beta-Lactamases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 71OTZ9ZE0A (Imipenem); EC 3.5.2.6 (beta-Lactamases); F93UJX4SWT (Ticarcillin)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160121
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.02171-15


  8 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26472688
[Au] Autor:Ye Q; Wu Q; Hu H; Zhang J; Huang H
[Ad] Endereço:School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, P. R. China Guangdong Institute of Microbiology; State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, P. R. China Guangdong Provincial Key Laboratory of Microbial Culture Collec
[Ti] Título:Prevalence, antimicrobial resistance and genetic diversity of Yersinia enterocolitica isolated from retail frozen foods in China.
[So] Source:FEMS Microbiol Lett;362(24):fnv197, 2015 Dec.
[Is] ISSN:1574-6968
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In this study, our aim was to estimate the extent of Yersinia enterocolitica contamination in frozen foods in China and determine the bioserotype, virulotype, antimicrobial resistance, and enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) genotyping profiles of recovered Y. enterocolitica isolates. Out of 455 samples collected between July 2011 and May 2014, 56 (12.3%) tested positive for Y. enterocolitica. The 70 isolated strains were grouped into five clusters and one singleton based on their ERIC-PCR fingerprint, at a similarity coefficient of 70%. All strains were of biotype 1A, and 35.7% were of bioserotype 1A/O:8. Most strains lacked the virulence genes ail, virF, ystA, and ystC, but harbored ystB, fepD, ymoA, fes and sat. All strains were sensitive to ticarcillin but resistant to two or more antibiotics, and 48.6% of the strains were resistant to four to nine antibiotics. High resistance rates were observed for ampicillin, cephalothin, trimethoprim/sulfamethoxazole, amoxicillin/clavulanic acid, nalidixic acid and chloramphenicol (98.6%, 95.7%, 74.3%, 28.6%, 18.6% and 12.9%, respectively). This study provides a systematic surveillance of Y. enterocolitica prevalence in frozen foods in China and indicates its high antibiotic resistance, which could serve as useful information for the government to control Y. enterocolitica contamination in frozen foods and the use of antibiotics.
[Mh] Termos MeSH primário: Microbiologia de Alimentos
Alimentos Congelados/microbiologia
Variação Genética
Yersinia enterocolitica/genética
Yersinia enterocolitica/isolamento & purificação
[Mh] Termos MeSH secundário: Ampicilina/farmacologia
Antibacterianos/farmacologia
China
Farmacorresistência Bacteriana Múltipla/genética
Genótipo
Carne/microbiologia
Testes de Sensibilidade Microbiana
Reação em Cadeia da Polimerase
Prevalência
Sorotipagem
Ticarcilina/farmacologia
Virulência/genética
Yersinia enterocolitica/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 7C782967RD (Ampicillin); F93UJX4SWT (Ticarcillin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151120
[Lr] Data última revisão:
151120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151017
[St] Status:MEDLINE


  9 / 993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26248364
[Au] Autor:Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
[Ad] Endereço:French National Reference Center for Antibiotic Resistance, University Hospital of Besançon, Besançon, France.
[Ti] Título:Mutations in ß-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
[So] Source:Antimicrob Agents Chemother;59(10):6248-55, 2015 Oct.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mutation-dependent overproduction of intrinsic ß-lactamase AmpC is considered the main cause of resistance of clinical strains of Pseudomonas aeruginosa to antipseudomonal penicillins and cephalosporins. Analysis of 31 AmpC-overproducing clinical isolates exhibiting a greater resistance to ceftazidime than to piperacillin-tazobactam revealed the presence of 17 mutations in the ß-lactamase, combined with various polymorphic amino acid substitutions. When overexpressed in AmpC-deficient P. aeruginosa 4098, the genes coding for 20/23 of these AmpC variants were found to confer a higher (2-fold to >64-fold) resistance to ceftazidime and ceftolozane-tazobactam than did the gene from reference strain PAO1. The mutations had variable effects on the MICs of ticarcillin, piperacillin-tazobactam, aztreonam, and cefepime. Depending on their location in the AmpC structure and their impact on ß-lactam MICs, they could be assigned to 4 distinct groups. Most of the mutations affecting the omega loop, the R2 domain, and the C-terminal end of the protein were shared with extended-spectrum AmpCs (ESACs) from other Gram-negative species. Interestingly, two new mutations (F121L and P154L) were predicted to enlarge the substrate binding pocket by disrupting the stacking between residues F121 and P154. We also found that the reported ESACs emerged locally in a variety of clones, some of which are epidemic and did not require hypermutability. Taken together, our results show that P. aeruginosa is able to adapt to efficacious ß-lactams, including the newer cephalosporin ceftolozane, through a variety of mutations affecting its intrinsic ß-lactamase, AmpC. Data suggest that the rates of ESAC-producing mutants are ≥1.5% in the clinical setting.
[Mh] Termos MeSH primário: Adaptação Fisiológica/genética
Antibacterianos/farmacologia
Proteínas de Bactérias/genética
Mutação
Pseudomonas aeruginosa/genética
Resistência beta-Lactâmica/genética
beta-Lactamases/genética
[Mh] Termos MeSH secundário: Adaptação Fisiológica/efeitos dos fármacos
Sequência de Aminoácidos
Substituição de Aminoácidos
Aztreonam/farmacologia
Proteínas de Bactérias/metabolismo
Ceftazidima/farmacologia
Cefalosporinas/farmacologia
Expressão Gênica
Testes de Sensibilidade Microbiana
Dados de Sequência Molecular
Ácido Penicilânico/análogos & derivados
Ácido Penicilânico/farmacologia
Piperacilina/farmacologia
Estrutura Secundária de Proteína
Estrutura Terciária de Proteína
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/metabolismo
Ticarcilina/farmacologia
beta-Lactamases/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Cephalosporins); 0 (ceftolozane, tazobactam drug combination); 157044-21-8 (piperacillin, tazobactam drug combination); 807PW4VQE3 (cefepime); 87-53-6 (Penicillanic Acid); 9M416Z9QNR (Ceftazidime); EC 3.5.2.6 (AmpC beta-lactamases); EC 3.5.2.6 (beta-Lactamases); F93UJX4SWT (Ticarcillin); G2B4VE5GH8 (Aztreonam); X00B0D5O0E (Piperacillin)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160401
[Lr] Data última revisão:
160401
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150807
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.00825-15


  10 / 993 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25858231
[Au] Autor:Grall N; Barraud O; Wieder I; Hua A; Perrier M; Babosan A; Gaschet M; Clermont O; Denamur E; Catzeflis F; Decré D; Ploy MC; Andremont A
[Ad] Endereço:INSERM, IAME, UMR 1137, F-75018, Paris, France.
[Ti] Título:Lack of dissemination of acquired resistance to ß-lactams in small wild mammals around an isolated village in the Amazonian forest.
[So] Source:Environ Microbiol Rep;7(5):698-708, 2015 Oct.
[Is] ISSN:1758-2229
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, we quantitatively evaluated the spread of resistance to ß-lactams and of integrons in small rodents and marsupials living at various distances from a point of antibiotic's use. Rectal swabs from 114 animals were collected in Trois-Sauts, an isolated village in French Guiana, and along a 3 km transect heading through the non-anthropized primary forest. Prevalence of ticarcillin-resistant enterobacteria was 36% (41/114). Klebsiella spp., naturally resistant to ticarcillin, were found in 31.1% (23/73) of animals from the village and in an equal ratio of 31.7% (13/41) of animals trapped along the transect. By contrast Escherichia coli with acquired resistance to ticarcillin were found in 13.7% (10/73) of animals from the village and in only 2.4% (1/41) of those from the transect (600 m from the village). There was a huge diversity of E. coli and Klebsiella pneumoniae strains with very unique and infrequent sequence types. The overall prevalence of class 1 integrons carriage was 19.3% (22/114) homogenously distributed between animals from the village and the transect, which suggests a co-selection by a non-antibiotic environmental factor. Our results indicate that the anthropogenic acquired antibiotic resistance did not disseminate in the wild far from the point of selective pressure.
[Mh] Termos MeSH primário: Animais Selvagens/microbiologia
Escherichia coli/efeitos dos fármacos
Transferência Genética Horizontal
Klebsiella pneumoniae/efeitos dos fármacos
Resistência beta-Lactâmica
[Mh] Termos MeSH secundário: Animais
Antibacterianos/farmacologia
Escherichia coli/isolamento & purificação
Florestas
Guiana Francesa
Klebsiella pneumoniae/isolamento & purificação
Marsupiais/microbiologia
Roedores/microbiologia
Seleção Genética
Ticarcilina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); F93UJX4SWT (Ticarcillin)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:151020
[Lr] Data última revisão:
151020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150411
[St] Status:MEDLINE
[do] DOI:10.1111/1758-2229.12289



página 1 de 100 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde